Aktuellt
SENASTE
We expect the momentum we saw in Q2 to continue in Q3 where we estimate 25% y/y growth. Looking forward, we find that SyntheticMR is well positioned to accelerate its growth and we expect growing licence revenues to produce attractive profitability down the line. We make minor negative estimate revisions across our forecast period and our new DCF-based fair value range is SEK 33-42 (prev. SEK 34-44).
LÄS MER
